HomeEmerging MarketsThe Market Everyone Gave...

The Market Everyone Gave Up On Is Crushing Nasdaq 100 In 2025 – Global X MSCI Greece ETF (ARCA:GREK), Invesco QQQ Trust, Series 1 (NASDAQ:QQQ)

Greece’s 2010 collapse was so severe it leased islands, gutted public jobs and pensions, while some abroad even joked about selling the Acropolis to appease creditors.

Fast forward 15 years, and the picture couldn’t be more different.

The Athens Stock Exchange has soared nearly 34% year-to-date, making Greece the world’s best-performing equity market thus far in 2025.

Meanwhile, the Global X MSCI Greece ETF GREK, the main U.S.-listed vehicle for investing in Greek stocks, has jumped a staggering 57% year-to-date, beating the Invesco QQQ Trust QQQ and Vanguard S&P 500 ETF VOO by about a 50-percentage-point margin.

Once the poster child of Europe’s debt crisis, Greece is now delivering the world’s hottest stock market rally.

Why Is Greek Stock Market Rallying In 2025?

Fiscal discipline, tax overhauls, and improved public administration have laid the groundwork for this resurgence. Major structural reforms, supported by funding from the European Union’s Next Generation EU plan, are also paying off.

The Greek economy is expected to grow 3.2% this year, according to the European Commission — more than double the eurozone average.

The real engine of the Greek stock market’s rally in 2025 has been the financial sector.

Greek banks, once considered radioactive by global investors, are now leading the charge. Alpha Bank S.A. is up 73% year-to-date, Piraeus Financial Holdings is up 72% and Optima Bank has soared 80%.

Is There Still Room To Run?

Despite the blistering rally in 2025, Greek stocks remain far from overheated. In fact, the Athens Stock Exchange is still trading 62% below its 2007 all-time high, leaving plenty of headroom for further gains.

That valuation gap hasn’t gone unnoticed by major Wall Street firms, which continue to back the Greek rebound. Goldman Sachs and Bank of America both argue that, despite a surge of 50% or more in bank stocks, the sector remains fundamentally undervalued.

According to Goldman Sachs analyst Mikhail Butkov, Greek banks are expected to deliver return on tangible equity (RoTE) of around 14% from 2025 to 2029. He also expects dividend payout ratios to rise to at least 50%, bad loan ratios (non-performing exposures, or NPEs) to fall to 3% next year and 2% by 2029, and capital levels (CET1 ratios) to remain healthy at 16%-17%.

Even with the European Central Bank signaling lower interest rates, Goldman believes Greek banks can still beat expectations.

“We believe this will be offset by stronger-than-expected lending growth, higher contribution from securities income and better spreads,” Butkov said.

Bank of America thinks the rally isn’t over yet.

Bank of America equity analyst Ilija Novosselsky wrote last week that Greek banks “still look cheap despite the rally” and listed several reasons why the upside may continue: net interest income (NII) is turning higher, fee income is growing at an 8.5% compound annual rate, earnings are boosted by mergers and acquisitions, risk costs (CoR) are falling and dividend payouts could reach 70%.

Novosselsky reiterated Buy ratings on Eurobank, Alpha Bank and Piraeus, naming Eurobank his top pick with 42% upside potential.

Fifteen years after the debt meltdown, Greece has finally shifted from fiscal tragedy to market opportunity.

Read Next:

Photo: sasirin pamai/Shutterstock

Most Popular

More from Author

Gold Prices Rise on Trump’s Tariff Threats and Fed Policy Uncertainty

Tariff-Related Inflation Risks Support Gold Gold () rose by over 0.35% on...

US Dollar Holds Steady as Trump Threatens 50% Tariffs on Brazil

Trump announces fresh round of tariffs on Brazil and smaller nations But...

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study – Pfizer (NYSE:PFE)

Pfizer Inc. PFE and Astellas Pharma Inc. ALPMF ALPMY on Thursday...

Read Now

Gold Prices Rise on Trump’s Tariff Threats and Fed Policy Uncertainty

Tariff-Related Inflation Risks Support Gold Gold () rose by over 0.35% on Wednesday. Markets remain focused on tariff demand letters from US President Donald Trump, with Brazil the latest country to face steep duties on and other imports. The tariffs have fuelled concerns about broader trade disruptions and...

FDA Grants Complete Approval To Moderna’s COVID-19 Vaccine For Children As Young As 6 Months – Moderna (NASDAQ:MRNA)

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s MRNA supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.The company’s COVID-19 vaccine, mRNA-1273, was previously available...

US Dollar Holds Steady as Trump Threatens 50% Tariffs on Brazil

Trump announces fresh round of tariffs on Brazil and smaller nations But only mild risk aversion as Nvidia (NASDAQ:) drives equities higher, hits $4 trillion cap Fed minutes erase July cut bets as doves in the minority, dollar supported Bitcoin hits record high, comes just shy of $112,000 Trump Stuck in...

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study – Pfizer (NYSE:PFE)

Pfizer Inc. PFE and Astellas Pharma Inc. ALPMF ALPMY on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence...

The Powell-Trump Clash is Set to Escalate

Growth challenges are mounting while tariffs will lift inflation, but stagflation fears are wide of the mark. The Fed will likely delay rate cuts until the end of the year, despite escalating pressure from the president, but may move in larger steps when it does cutConsumer Caution...

Why Is AbbVie Stock Trading Higher On Thursday? – AstraZeneca (NASDAQ:AZN), AbbVie (NYSE:ABBV)

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.“Multispecifics including trispecific antibodies represent...

Dynamic Hedging and FX Risk Analysis Within Tactical Asset Allocation Rules

Often, investors fully hedge their portfolios for currency risk. This can lead to significant drag in performance for currencies with negative carry. However, not hedging the foreign currency exposure can lead to significant drawdowns, especially for conservative investments. In this paper, we consider a conservative, global tactical...

German CPI Confirmed at 2.0%, Euro Drifting, FOMC Split Over Cuts

The euro continues to have a quiet week and is drifting for a third consecutive day. In the European session, is trading at 1.1730, up 0.09% on the day.German Inflation Dips to 2% as food, Energy Prices FallGerman inflation rose 2.0% y/y in June, in line...

Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble? – Klotho Neurosciences (NASDAQ:KLTO)

Shares of Klotho Neurosciences, Inc. KLTO have soared more than 1000% over the past three months on promising results and breakthrough hopes. Klotho stock was in the spotlight again Thursday after announcing an FDA nod on its ALS treatment candidate. What's Driving The Rally: Klotho announced it has received...

Eurozone Economic Weakness Laid Bare as US Front-Loading Effects Wane

Eurozone data remains volatile amid trade war developments, but the underlying trend is still sluggish. Uncertainty is slowing domestic demand, which contributes to our expectation of a further rate cut from the European Central Bank in SeptemberEurozone Economy Shows Further Weakness in the Second QuarterThe eurozone economy...

SeaStar Medical’s QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka – Johnson & Johnson...

When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern. That's particularly true regarding pediatric AKI – each year, about 4,000 children with AKI require continuous renal replacement therapy (RRT), with a mortality rate of approximately 51-58%. Many of those...

Why Are Biotech Stocks Ultragenyx And Mereo Facing A Sell-Off? – Ultragenyx Pharmaceutical (NASDAQ:RARE), Mereo BioPharma Group (NASDAQ:MREO)

Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday.What Happened?The companies on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward...